Track all markets on TradingView
Evaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts
Media

Evaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts

  • November 6, 2024
  • 10 Views

Latest Ratings for RARE

Date Firm Action From To
Feb 2022 Morgan Stanley Maintains Overweight
Feb 2022 JP Morgan Upgrades Neutral Overweight
Feb 2022 Morgan Stanley Maintains Overweight

View More Analyst Ratings for RARE

View the Latest Analyst Ratings

read more

​ 

​Latest Ratings for RARE
DateFirmActionFromTo Feb 2022Morgan StanleyMaintainsOverweight Feb 2022JP MorganUpgradesNeutralOverweight Feb 2022Morgan StanleyMaintainsOverweight
View More Analyst Ratings for RARE

View the Latest Analyst Ratings

read more 

Share This Post:

Leave a Reply

Your email address will not be published. Required fields are marked *

This material is for informational purposes is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. The opinions expressed are as of date of publication and are subject to change. Reliance upon information in this material is at the sole discretion of the reader. Past performance is not indicative of current or future results. This information provided is neither tax nor legal advice and investors should consult with their own advisors before making investment decisions. Investment involves risk including possible loss of principal.